Abstract
The central role played by cells of the mononuclear phagocyte system (MPS) such as alveolar macrophages, hepatic Kupffer cells, splenic and lymph node macrophages, tissue histiocytes and circulating blood monocytes in the complex host reaction to neoplastic and infectious diseases has attracted increasing attention during the past 10 years. This interest stems from the experimental studies illustrating that macrophages when appropriately activated* play a major role in host defense against tumors and infectious microorganisms in vivo and also display enhanced tumoricidal and microbicidal activity in vitro 1–3. These observations, coupled with the disappointing results obtained in both clinical and experimental studies with immunologically-specific therapeutic modalities mediated by T and B lymphocytes in cancer immunotherapy has led to a renewed interest in the functions of macrophages and NK cells. Additionally, there is needed a reappraisal of the potential therapeutic benefit of augmenting non-specific host defense mechanisms mediated by mononuclear phagocytes for adjunct therapy of neoplastic and infectious diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Pick, E. (ed.), Lymphokines, Vol. 3, Academic Press, NY, (1981).
Poste, G., and Fidler, I.J., The pathogenesis of cancer metastasis, Nature, 283:139–146, (1980).
Fidler, I.J., and Poste, G., Macrophase-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease, Springer Semin. Immunopathol., 5:161–174, (1982).
Chirigos, M.A., Mitchell, M., Mastrangelo, M.J., Krim, M. (Eds.), Modulation of Cellular Immunity in Cancer by Immune Modifiers, Raven Press, NY, (1981).
Ehrlich, P., Collected Studies on Immunity, Reprinted, Wiley, NY, Vol. 2, pp. 442–447, (1906).
Gregoriadis, G., Sr., and Trouet, A. (Eds.), Targeting of Drugs, Plenum Press, NY, (1982).
Bruck, S.D. (Ed.), Controlled Drug Delivery, CRC, Boca Raton, (1982).
Gregoriadis, G., and Allison, A.C. (Eds.), Liposomes in Biological Systems, Wiley Interscience, NY, (1980).
Poste, G., and Kirsh, R., Site-specific (targeted) drug delivery in cancer therapy, Biotechnology. 1:869–878, (1983).
Szoka, F., and Papahadjopoulos, D., Liposomes. Preparation and characterization, in Liposomes: From Physical Structure to Therapeutic Applications, C. G. Knight (Ed.), Elsevier, Amsterdam, pp. 51–82, (1981).
Hauser, H., Methods of preparation of lipid vesicles: assessment of their suitability for drug encapsulation, Trends Pharm. Sci., 3:274–277, (1982).
Leserman, L.D., Machy, P., Pevaux, C., and Barbet, J., Antibody-bearing liposomes: targeting in vivo. Biol. Cell, 47:111–116, (1983).
Poste, G., Liposome targeting invivo: problems and opportunities, Biol. Cell. 47:19–30, (1983).
Poste, G., Kirsh, R., and Koestler, T., The challenge of liposome targeting in vivo, in Liposome Technology, G. Gregoriadis (Ed.), CRC Press, Boca Raton, FLA, pp. 1–28, (1983).
Poste, G., Kirsh, R., Fogler, W.E., and Fidler, I.J., Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery, Cancer Res., 42:1412–1422, (1982).
Scherphof, G.L., Interaction of liposomes with biological fluids and fate of liposomes in vivo. in Liposome Methodology, L.D. Leserman and J. Barbet (Eds.), pp. 79–92, Inserm, Paris, (1982).
Altura, B.M., Reticuloendothelial cells and host defense.
Taylor, R.L., Hilliams, D.M., Craven, P.C., Graybill, J.R., Drutz, P.J., and Magee, N.E., Amphotericin B in liposomes; a novel therapy for histoplasmosis, Am. Rev. Respir. Dis 125:610–611 (1982).
New, R.R.C., Chance, M.L., and Heath, S., The treatment of experimental cutaneous leishmaniasis with liposome-entrapped Pentostam, Parasitol. 83:519–527 (1981).
Lopez-Berestein, G., Mehta, R., Hopfer, R.L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M. Hersh, E.M., and Juliano, R., Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposomne-encapsulated amphotericin B, J. Infect. Dis. 5:939–945 (1983).
Graybill, J.R., Craven, P.C., Taylor, R.L., Hilliams, P.M., and Magee, N.E., KTreatment of murine cryptococcosis with liposome associated amphotericin B, J. Infect. Dis. 145: 748–751 (1982).
Fountain, M.H., Pees, C., and Schultz, R.P., Enhanced intracellular killing of Staphylococcus aureus by canine monocytes treted with liposome containing amikacin, gentamicin, kanamycin, and tobramycin, Current Microbiol. 6:373–376 (1981).
Alving, C.R., and Steck, E.A., The use of liposome-encapsulated drugs in leishmaniasis, Trends Biochem. Sci. 4:N175–177 (1979).
Pesiderio, J.V., and Campbell, S.G., Liposome-encapsulated cephalothin in the treatment of experimental murine salmonellosis, RES: Journal of the Reticuloendothelial Society 34:279–287 (1983).
Bodey, G.P., Fungal infections complicating acute leukemia, J. Chron. Dis. 19:667 (1966).
Degregorio, M.W., Lee, N.M.F., Linker, C.A., Jacobs, R.A., and Ries, C.A., Fungal infections in patients with acute leukemia, Am. J. Med. 73:543–548 (1982).
Louria, D.B., and Sen, P., Fungal infections with a particular focus on the compromised host, Del. Med. J. 54:11–19 (1982).
Alexander, P., and Evans, R., Endotoxin and double stranded RNA render macrophages cytotoxic, Nature New Biology 232:76–78 (1971).
Cleveland, R.P., Meltzer, M.S., and Zbar, B., Tumor cytotoxicity in vitro by macrophages from mice infected with Mycobacterium bovis strain BCG, J. Nat. Cancer Inst. 52:1887–1894 (1974).
Scott, M.T., In vivo cortisone sensitivity of nonspecific antitumor activity of Corynebacteria parvum activated mouse peritoneal macrophages, J. Nat. Cancer Inst. 54:789–792 (1975).
Sone, S., and Fidler, I.J., In situ activation of tumoricidal properties in rat alveolar macrophages and rejection of experimental lung metastases by intravenous injections of Nocardia rubra cell wall skeleton, Cancer Immunol. Immunother. 12:203–209 (1982).
Lederer, E., Synthetic immunostimulants derived from the bacterial cell wall, J. Med. Chem. 23:819–825 (1980).
Parant, M., Parant, F., Chedid, L., Yapo, A., Petit, J.F., and Lederer, L., Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse, Int. J. Immunopharmacol 1:35–41 (1979).
Poste, G., Kirsh, R., and Fidler, I.J., Cell surface receptors for lymphokines, Cell Immunol 44:72–88 (1979).
Papermaster, B.N., Holterman, O.A., and Klein, E., Preliminary observations on tumor regressions induced by local administration of a lymphoid cell culture supernatant fraction in patients with cutaneous metastatic lesions, 5:31–35 (1976).
Fidler, I.J., and Raz, A., The induction of tumoricidal capacities in mouse and rat macrophages by lymphokines, in Pick, E. (Ed.), Lymphokines, Vol. 3, Academic Press, New York, pp. 345–364 (1981).
Poste, G., and Kirsh, R., Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages, Cancer Res. 39:2582–2590 (1979).
Poste, G., The tumoricidal properties of inflammatory tissue macrophages and multinucleate giant cells, Am. J. Pathol 96:595–608 (1979).
Poste, G., and Fidler, I.J., Active non-specific immunotherapy of lung metastases by macrophage activating agents encapsulated in liposome, in Optimization of Drug Delivery, A. Benzon, Symposium No. 17, H. Bundgaard, A. Hansen, and H. Kofod (Eds.), Bundgaard, Copenhage, pp. 48–429 (1982).
Koff, W.C., Showalter, S.D., Seniff, D.A., and Hampar, B., Lysis of Herpesvirus-infected cells by macrophages activated with free or liposome-encapsulated lymphokine produced by a murine T cell hybridoma, Infection and Immunity 42:1067–1072 (1983).
Koff, W.C., Fidler, I.J,, Showalter, S.D., Chakrabarty, M.K., Hampar, B., Ceccorulli, L.M., and Kleinerman, E.S., Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells, Science 224:1007–1009 (1984).
Alving, C.R., and Richards, R.L., Immunological aspects of liposomes, in The Liposomes., M. Ostro, ed., M. Dekker, New York (In Press) (1983).
Federal Register, Food and Drug Administration, Proposed new drug, antibiotic and biologic drug product regulations, 48:26720–749 (June 9, 1983) (1983).
Juliano, R.L., Lopez-Berenstein, G., Mehta, R., Hopfer, R., Mehta, K., and Kasi, L., Pharmacokinetic and therapeutic consequences of liposomal drug delivery: fluorodeoxyuridine and amphotericin B as examples, Biol. Cell 47: 39–46 (1983).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Kirsh, R., Poste, G. (1986). Liposome Targeting to Macrophages: Opportunities for Treatment of Infectious Diseases. In: Actor, P., Evangelista, A., Poupard, J., Hinks, E. (eds) Infections in the Immunocompromised Host. Advances in Experimental Medicine and Biology, vol 202. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1259-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1259-8_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1261-1
Online ISBN: 978-1-4684-1259-8
eBook Packages: Springer Book Archive